Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Pugar

Neurology Dayton, OH Doctor of Osteopathy

NPI 1174961874 CMS profile 1379203

405 W Grand Ave, Dayton, OH 45405

Open in the dashboard

General payments

$22,959

1,115 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,500 paid to institutions, not to them · program year 2019

Through program year 2025, Kenneth Pugar of Dayton, OH is reported in the CMS Open Payments database as having received $22,959 across 1,115 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,500 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,120 121
2024 General $3,260 142
2023 General $3,254 147
2022 General $5,529 181
2021 General $3,179 206
2020 General $1,592 112
2019 General $3,025 206

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Pugar
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Kenneth Pugar were reported at $3,120. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Kenneth Pugar Neurology median Middle half National median
2019 $3,025 $474 $118–$2,177 $163
2020 $1,592 $367 $82–$2,309 $114
2021 $3,179 $438 $104–$2,547 $132
2022 $5,529 $442 $103–$2,388 $149
2023 $3,254 $464 $119–$2,312 $160
2024 $3,260 $468 $119–$2,323 $164
2025 $3,120 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Eisai Inc. $2,520 20 payments
  2. AbbVie, Inc. $2,387 109 payments
  3. EMD Serono, Inc. $1,760 51 payments
  4. Novartis Pharmaceuticals Corporation $1,501 106 payments
  5. US WorldMeds, LLC $1,376 79 payments
  6. Supernus Pharmaceuticals, Inc. $1,005 68 payments
  7. UCB, Inc. $1,003 41 payments
  8. SK Life Science, Inc. $839 49 payments
  9. Teva Pharmaceuticals USA, Inc. $736 38 payments
  10. Biogen, Inc. $693 40 payments
  11. Other $9,139 514 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $20,537 1,091 payments
  2. Consulting Fee $2,160 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $162 18 payments
  4. Education $100 5 payments
Products named General payments · program years 2019–2025
  1. QULIPTA $1,568 65 payments
  2. UBRELVY $1,040 43 payments
  3. TROKENDI XR $987 67 payments
  4. Gocovri $860 31 payments
  5. AIMOVIG $760 52 payments
  6. KESIMPTA Neuroscience $623 52 payments
  7. Briviact $572 23 payments
  8. NURTEC ODT $532 35 payments
  9. KESIMPTA Neurology $441 19 payments
  10. BOTOX $437 36 payments
  11. Other $11,906 669 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

726

Median for Neurology: 833

Drug cost

$146,485

Median for Neurology: $202,670

Branded share of claims

24.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Botox Onabotulinumtoxina Brand 36 $54,127
Nurtec Odt Rimegepant Sulfate Brand 25 $37,472
Qulipta Atogepant Brand 30 $33,014
Aimovig Autoinjector Erenumab-Aooe Brand 12 $9,099
Pyridostigmine Bromide Generic 20 $1,576
Entacapone Generic 11 $1,505
Memantine Hcl Generic 57 $1,482
Pregabalin Generic 30 $1,404
Gabapentin Generic 107 $1,095
Carbidopa-Levodopa Carbidopa/Levodopa Brand 37 $848

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$153,039

Of which drugs: $88,630

Medicare patients

418

Average age 75

Services billed

8,586

246 women, 172 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Depression 44%
Ischemic heart disease 42%
Diabetes 41%
Chronic kidney disease 36%
Heart failure 33%
Alzheimer's or dementia 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 15 6,700 $30,574

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 39 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Gocovri
$816 — —
QULIPTA
$253 30 —
KESIMPTA
$173 — —
Briviact
$170 — —
UBRELVY
$159 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 39 with Patron

Records

1,115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record